Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries expects a single-digit decline in consolidated revenues for FY18 since the short-term outlook continues to be challenging as the US generics industry is facing rapidly changing market dynamics.

The increased competitive intensity and customer consolidation is leading to pressure on pricing, while continued delay in approvals from the Halol facility is also impacting the company’s working.

Sun Pharmaceutical Industries is the world’s fourth largest specialty generic pharmaceutical company and India’s top pharmaceutical company.